Effects of non-convulsive electroconvulsive therapy combined with ziprasidone on cognitive function and neurotransmitter in patients with schizophrenia
Objective:To investigate the effects of non-convulsive electroconvulsive therapy combined with ziprasidone on cognitive function and neurotransmitters in patients with schizophrenia.Methods:A total of 74 patients with schizophrenia admitted to our hospital from March 2021 to March 2023 were randomly divided into a control group and a study group(n=37).The control group was treated with oral ziprasidone 20 mg,while the study group was treated with non-convulsive electroconvulsive therapy combined with ziprasidone 20 mg.After 3 months of treatment,the clinical efficacy of the two groups was analyzed and compared based on the reduction rate of positive and negative symptom scales.The cognitive function was measured using a systematic software-generated set of cognitive function tests including the maze test(MAZES),trail-making test B(TMT-B),continuous performance test(CPT),and symbol coding test(SC).The levels of dopamine(DA),glutamic acid(Glu),and gamma-aminobutyric acid(GABA)were measured using a 16-channel multi-function electroencephalograph.The levels of serum interleukin-6(IL-6),tumor necrosis factor-α(TNF-α),and transforming growth factor-β1(TFG-β1)were measured using enzyme-linked immunosorbent assay.Results:The total effective rate of the study group was significantly higher than that of the control group(P<0.05).Compared with before treatment,MAZES,MTT-B,CPT,SC scores,and Glu and GABA levels were significantly increased in all treatment groups,while DA,IL-6,TNF-α,and TFG-β1 levels were significantly decreased(P<0.05),especially in the study group(P<0.05).Conclusion:The application of non-convulsive electroconvulsive therapy combined with ziprasidone in the treatment of schizophrenia can improve efficacy,enhance cognitive function,improve neurotransmitters,and alleviate inflammatory reactions.
万方数据
维普
